scispace - formally typeset
B

B. Mark Smithers

Researcher at University of Queensland

Publications -  134
Citations -  9316

B. Mark Smithers is an academic researcher from University of Queensland. The author has contributed to research in topics: Melanoma & Cancer. The author has an hindex of 32, co-authored 112 publications receiving 7853 citations. Previous affiliations of B. Mark Smithers include QIMR Berghofer Medical Research Institute & Princess Alexandra Hospital.

Papers
More filters
Journal ArticleDOI

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis

TL;DR: This updated meta-analysis provides strong evidence for a survival benefit of neoadjuvant chemoradiotherapy or chemotherapy over surgery alone in patients with oesophageal carcinoma and investigates treatment effects by tumour histology and relations between risk (survival after surgery alone) and effect size.
Journal ArticleDOI

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis

TL;DR: A significant survival benefit was evident for preoperative chemoradiotherapy and, to a lesser extent, for chemotherapy in patients with adenocarcinoma of the oesophagus and the findings provide an evidence-based framework for the use of neoadjuvant treatment in management decisions.
Journal ArticleDOI

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

Mark B. Faries, +58 more
TL;DR: Immediate completion lymph‐node dissection increased the rate of regional disease control and provided prognostic information but did not increase melanoma‐specific survival among patients with melanoma and sentinel‐node metastases.
Journal ArticleDOI

Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

TL;DR: Preoperative chemoradiotherapy with cisplatin and fluorouracil does not significantly improve progression-free or overall survival for patients with resectable oesophageal cancer compared with surgery alone, and further assessment is warranted of the role of cheMoradiotherapy in patients with squamous-cell tumours.